Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias - PubMed (original) (raw)
Clinical Trial
. 2010 Dec 2;116(23):4783-5.
doi: 10.1182/blood-2010-06-291831. Epub 2010 Sep 14.
Affiliations
- PMID: 20841509
- DOI: 10.1182/blood-2010-06-291831
Free article
Clinical Trial
Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias
David Gómez-Almaguer et al. Blood. 2010.
Free article
Abstract
Treatment of autoimmune cytopenias remains unsatisfactory for patients refractory to first-line management. We evaluated the safety and efficacy of low-dose rituximab plus alemtuzumab in patients with steroid-refractory autoimmune hemolytic anemia and immune thrombocytopenic purpura. Nineteen of 21 included patients were assessable for response (11 with immune thrombocytopenic purpura, 8 with autoimmune hemolytic anemia). Treatment with 10 mg of alemtuzumab subcutaneously on days 1 to 3, plus 100 mg of rituximab intravenously weekly in 4 doses, was administered. The overall response rate was 100%, with complete response in 58%. The median response duration was 46 weeks (range, 16-89 weeks). Median follow-up was 70 weeks (range, 37-104 weeks). Most toxicity was grade 1 fever related to the first dose. Six patients developed infections. The combination of rituximab and alemtuzumab is feasible and has an acceptable safety profile and remarkable clinical activity in this group of patients. This study is registered at www.clinicaltrials.gov as #NCT00749112.
Similar articles
- Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
Osterborg A, Karlsson C, Lundin J. Osterborg A, et al. Curr Hematol Malig Rep. 2009 Jan;4(1):47-53. doi: 10.1007/s11899-009-0007-4. Curr Hematol Malig Rep. 2009. PMID: 20425438 Review. - Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia.
Rossignol J, Michallet AS, Oberic L, Picard M, Garon A, Willekens C, Dulery R, Leleu X, Cazin B, Ysebaert L. Rossignol J, et al. Leukemia. 2011 Mar;25(3):473-8. doi: 10.1038/leu.2010.278. Epub 2010 Dec 3. Leukemia. 2011. PMID: 21127498 - Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults.
Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Provan D, et al. Haematologica. 2007 Dec;92(12):1695-8. doi: 10.3324/haematol.11709. Haematologica. 2007. PMID: 18055995 - [The effectiveness of rituximab in refractory autoimmune thrombocytopenic purpura and haemolytic anaemia].
Martínez Velasco E, Gómez Castillo JJ, Fernández Megía MJ, González Joga B, Barreda Hernández D, Gómez Roncero MI. Martínez Velasco E, et al. Farm Hosp. 2007 Mar-Apr;31(2):124-7. doi: 10.1016/s1130-6343(07)75724-0. Farm Hosp. 2007. PMID: 17590122 Spanish. - Monoclonal antibodies in the treatment of autoimmune cytopenias.
Robak T. Robak T. Eur J Haematol. 2004 Feb;72(2):79-88. doi: 10.1046/j.0902-4441.2003.00196.x. Eur J Haematol. 2004. PMID: 14962245 Review.
Cited by
- Evans syndrome: clinical perspectives, biological insights and treatment modalities.
Jaime-Pérez JC, Aguilar-Calderón PE, Salazar-Cavazos L, Gómez-Almaguer D. Jaime-Pérez JC, et al. J Blood Med. 2018 Oct 10;9:171-184. doi: 10.2147/JBM.S176144. eCollection 2018. J Blood Med. 2018. PMID: 30349415 Free PMC article. Review. - [Alemtuzumab: a further option for treatment of multiple sclerosis].
Menge T, Kieseier BC, Warnke C, Aktas O, Hartung HP. Menge T, et al. Nervenarzt. 2012 Apr;83(4):487-501. doi: 10.1007/s00115-011-3393-5. Nervenarzt. 2012. PMID: 22038387 German. - Autoimmune hemolytic anemia: current knowledge and perspectives.
Michalak SS, Olewicz-Gawlik A, Rupa-Matysek J, Wolny-Rokicka E, Nowakowska E, Gil L. Michalak SS, et al. Immun Ageing. 2020 Nov 20;17(1):38. doi: 10.1186/s12979-020-00208-7. Immun Ageing. 2020. PMID: 33292368 Free PMC article. Review. - Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
Vianelli N, Auteri G, Buccisano F, Carrai V, Baldacci E, Clissa C, Bartoletti D, Giuffrida G, Magro D, Rivolti E, Esposito D, Podda GM, Palandri F. Vianelli N, et al. Ann Hematol. 2022 May;101(5):963-978. doi: 10.1007/s00277-022-04786-y. Epub 2022 Feb 24. Ann Hematol. 2022. PMID: 35201417 Free PMC article. Review. - Second-line therapy in paediatric warm autoimmune haemolytic anaemia. Guidelines from the Associazione Italiana Onco-Ematologia Pediatrica (AIEOP).
Ladogana S, Maruzzi M, Samperi P, Condorelli A, Casale M, Giordano P, Notarangelo LD, Farruggia P, Giona F, Nocerino A, Fasoli S, Casciana ML, Miano M, Tucci F, Casini T, Saracco P, Barcellini W, Zanella A, Perrotta S, Russo G; AIHA Committee of the Associazione Italiana di Ematologia ed Oncologia Pediatrica. Ladogana S, et al. Blood Transfus. 2018 Jul;16(4):352-357. doi: 10.2450/2018.0024-18. Epub 2018 Apr 13. Blood Transfus. 2018. PMID: 29757134 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources